Printer Friendly

Study: ExThera Device Cleans Cytomegalovirus from CMV-Spiked Whole Blood.

M2 PHARMA-January 28, 2015-Study: ExThera Device Cleans Cytomegalovirus from CMV-Spiked Whole Blood

(C)2015 M2 COMMUNICATIONS

US-based biomimetic device developer ExThera Medical Corp.'s Seraph Microbind Affinity Blood Filter (Seraph) was shown in a study to have quickly removed Cytomegalovirus from CMV-spiked whole blood, the company said on Wednesday.

ExThera said that the study results were presented at the 2015 44th Critical Care Congress of the Society for Critical Care Medicine.

Over a million new cases of sepsis are identified in the US annually, with an equally large case population in Europe and Asia. It is one of the top-ten causes of death in the US, killing over 225,000 Americans each year, more than lung and breast cancer combined.

Severe sepsis has reported mortality rates ranging from 30% to 60%, at an average treatment cost of USD 22,000 per case, representing 40% of all ICU costs.

In addition to early treatment of bloodstream infections to prevent sepsis, Seraph, a dialysis-like therapy, is potentially useful in treating cytomegalovirus reactivation during severe sepsis, and in patients with compromised immune systems from other causes.

In late-stage sepsis, 24% of the patients test positive for CMV viremia, ExThera said.

Since 2008, privately funded ExThera (short for Extracorporeal Therapy) has been developing new tools to treat a wide range of bloodstream infections caused by both bacteria and viruses.

ExThera's Seraph Microbind Affinity Blood Filter (Seraph), which the company said is now fully developed and about to enter clinical trials, is a broad-spectrum 'hemoperfusion' device with demonstrated ability to bind and remove a long list of disease-causing agents, including toxins, fungi and inflammatory cytokines.

Privately held ExThera Medical, based in Berkeley, Calif., is targeting the clinical treatment of blood-borne diseases including bacteremia and viremia, as well as the removal of harmful substances present in banked human blood.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 28, 2015
Words:314
Previous Article:Blue Belt Technologies Knee System Awarded CE Mark.
Next Article:Keltjens Named Interim CEO at JenaValve.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters